The business integration of DAIICHI and SANKYO brings together two pharmaceutical companies bound by a century of vision and a legacy of firsts. From the discovery of epinephrine to the development of the statin class of lipid-lowering agents, and the development of the first glitazone, which revolutionized long-term control of type 2 diabetes, the people of DAIICHI SANKYO remain committed to a unique ideal - a Global Pharma Innovator. - To physicians, this means objective data, the highest ethical standards, and a desire to deliver practical human benefits with each product we develop.
- To our partners, we balance the strength and stability of our global presence with the spirit, agility, and quick reaction times of much smaller companies.
- To our employees, we offer an operational structure that balances creativity with discipline and individualism with collaboration.
- To patients, we are committed to developing medications that put lives into balance and add to the balance of life.
We believe good science walks hand-in-hand with humanity and, as we move forward into our next century, we seek to build on our history of discovery with the development of new therapies in cardiovascular disease, cancer, metabolic disorders and infection. Range of products DAIICHI SANKYO has its core expertise in the development of drugs for the treatment of cardiovascular disease (CVD), dyslipidemia and infectious diseases. Further important fields of research are oncology, immunology / allergy and bone / joint diseases. The following passage gives a short overview of our medicinal products. |
